As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Several factors are associated with increased mortality in patients with bullous pemphigoid, with mortality rates increasing 5 years after diagnosis.

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

Cutaneous immune-related adverse events that develop after immune checkpoint inhibitor therapy become chronic in nearly ...

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous ...

Bullous pemphigoid (BP) is a well-known condition triggered by autoantibodies directed against hemidesmosomal proteins involved in the adhesion of basal keratinocytes to the basement membrane.

Joseph Saseen, PharmD, discussed the importance of knowing lipoprotein a (Lp[a]) levels to enable clinicians to provide the best patient care and spread awareness to those who might be affected ...

Dupilumab use among adults with bullous pemphigoid was associated with significant improvements in several efficacy measures, with no new safety signals identified. Dupilumab offers significant ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is engaged in discovering, inventing, developing, manufacturing, and commercializing medicines for treating various diseases. Dupixent® has been ...